A provider-focused briefing on the Leuprolide (Lupron Depot) shortage in 2026: timeline, affected formulations, prescribing alternatives, and patient support tools.
Leuprolide acetate — most commonly prescribed as Lupron Depot (AbbVie) — remains one of the most widely used GnRH agonists in US clinical practice. It's a foundational therapy across urology, oncology, gynecology, and pediatric endocrinology. Unfortunately, it's also been one of the most persistently supply-constrained specialty medications over the past six years.
This briefing provides prescribers with a current overview of the shortage, its clinical implications, available alternatives, and tools to help maintain continuity of care for your patients.
The Leuprolide shortage was first tracked by the American Society of Health-System Pharmacists (ASHP) in 2020. Here's how it has evolved:
The ongoing supply instability has several practical implications for prescribers:
Patients on maintenance GnRH agonist therapy — particularly those being treated for advanced prostate cancer or central precocious puberty — face real clinical risk if injections are delayed or missed. Testosterone rebound in prostate cancer can lead to disease progression, while interruption of puberty suppression can cause premature pubertal advancement.
The shortage does not affect all Leuprolide products equally. Key distinctions:
Switching patients to alternative formulations or therapeutic alternatives often triggers new prior authorization requirements. In a time-sensitive situation, this administrative burden can delay treatment. Proactively documenting the shortage and medical necessity in your notes can facilitate faster approvals.
As of early 2026, the availability landscape looks like this:
Leuprolide is a high-cost specialty medication, and the shortage can compound financial barriers for patients:
Most Leuprolide is billed under the medical benefit (buy-and-bill). Medicare Part B covers it with 20% patient coinsurance. AbbVie offers a copay savings card reducing commercially insured patient cost to as low as $10 per injection.
For patients facing financial hardship, AbbVie's Patient Assistance Foundation can provide the medication at no cost to qualifying uninsured or underinsured patients. More details at abbvie.com/PatientAccessSupport.
For a comprehensive breakdown of savings options to discuss with patients, see our provider's guide to helping patients save on Leuprolide.
Medfinder offers real-time pharmacy availability tracking that can help your staff and patients locate Leuprolide and alternative formulations in stock. This is particularly useful when your primary distributor is unable to fill an order.
The ASHP Drug Shortages Resource Center provides the most current shortage status, estimated resupply dates (when available), and clinical guidance for managing patients during supply disruptions.
AbbVie's provider support team can assist with locating inventory, navigating reimbursement, and connecting patients with assistance programs. Visit abbvieaccess.com or call the Lupron support line.
Several factors may influence the Leuprolide supply landscape in the coming years:
The Leuprolide shortage requires prescribers to be proactive in treatment planning, flexible in formulation selection, and prepared to advocate for their patients through prior authorization processes. Building awareness of the full range of GnRH analogs — agonists and antagonists, injectable and oral — will serve your patients well during this period of constrained supply.
For patient-facing resources on finding Leuprolide, you can direct patients to our guides on finding Leuprolide in stock and the 2026 shortage update for patients. For provider tools, visit medfinder.com/providers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
